Scarica l'app Stockscreener
1.42
4.25%
-0.063
Dopo l'orario di chiusura:
1.40
-0.02
-1.41%
Nls Pharmaceutics Ltd Borsa (NLSP) Ultime notizie
NLS Pharmaceutics to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest - ACCESS Newswire
What's Going On With NLS Pharmaceutics Shares Monday? - Benzinga
NLS Pharmaceutics Secures $3 Million Financing and $25 Million Equity Facility - TipRanks
NLS Pharmaceutics secures $2M for Kadimastem merger - Investing.com
NLS Pharmaceutics secures $2M for Kadimastem merger By Investing.com - Investing.com Canada
NLS Pharmaceutics and Kadimastem Announces Up to $3 Million Equity Financing and $25 Million Equity Facility Agreement - StreetInsider
Major Funding Breakthrough: NLS Pharmaceutics Raises $28M for Revolutionary ALS Treatment Development - Stock Titan
NLSP stock touches 52-week low at $1.47 amid market challenges By Investing.com - Investing.com South Africa
NLSP stock touches 52-week low at $1.47 amid market challenges - Investing.com India
NLS Pharmaceutics Ltd. (NASDAQ:NLSPW) Short Interest Down 31.6% in February - Defense World
NLS Pharmaceutics announces merger with Kadimastem By Investing.com - Investing.com Canada
NLS Pharmaceutics Announces Strategic Merger and Advances in Therapeutic Pipeline - TipRanks
NLS Pharmaceutics CEO Issues Letter to Shareholders - Quantisnow
NLS Pharmaceutics announces merger with Kadimastem - Investing.com India
NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce Filing of F-4 Registration Statement with the SEC Ahead of Proposed Merger - Marketscreener.com
NLSP stock touches 52-week low at $1.71 amid steep annual decline - Investing.com
NLSP stock touches 52-week low at $1.71 amid steep annual decline By Investing.com - Investing.com South Africa
NLS Pharmaceutics Announces Receipt of Additional Staff Delisting Determination from Nasdaq - ACCESS Newswire
NLS Pharmaceutics Announces Compliance with Nasdaq Bid Price Requirement - ACCESS Newswire
AEX-2 increases total wake duration in mouse model - BioWorld Online
NLS Pharmaceutics Announces $20 Million Standby Equity Distribution Agreement and $2.5 Million Equity Investment - ACCESS Newswire
NLS Pharmaceutics reports progress in narcolepsy treatment By Investing.com - Investing.com South Africa
NLS Pharmaceutics reports progress in narcolepsy treatment - Investing.com
Can NLS Pharmaceutics' Orexin Agonist Treat More Than Just Sleep Disorders? New Data Says Yes - StockTitan
NLS Pharmaceutics and Partners Achieve Milestone in Diabetes Treatment Development - MSN
Kadimastem and iTolerance Successfully Complete Pre-IND Meeting with the FDA for its Type 1 Diabetes Treatment - PR Newswire
NLS Pharmaceutics Announces Notice of Allowance for U.S. Patent Covering Mazindol for Opioid Dependence and Substance Use Disorder - ACCESS Newswire
NLS Pharmaceutics And Kadimastem Unveil Multi-Target Diabetes Approach - Nasdaq
Is NLSP’s price to cash per share ratio a concern for investors? - US Post News
NLS Pharmaceutics Ltd’s Shares Reel: -37.16% Quarterly Revenue Decline Amid 6.35M Market Cap - The InvestChronicle
NLS Pharmaceutics Ltd (NLSP) Shares Rise Despite Market Challenges - The News Heater
Stock market today: Patriot National Bancorp +46.21%, NLS Pharmaceutics +37.43% among top gainers in early trading - Business Upturn
NLS Pharmaceutics and Kadimastem Unveil Multi-Target Approach to Diabetes, Expanding Beyond GLP-1 Therapies - GuruFocus.com
NLS Pharmaceutics (NLSP) Shares Surge As Market Reacts To Potential Merger - Stocks Telegraph
NLS Pharmaceutics and Kadimastem Announce Merger to Innovate Diabetes Treatment - TipRanks
NLS and Kadimastem to merge, aim for diabetes care innovation - Investing.com
Are NLS Pharmaceutics Ltd’shares a good deal? - US Post News
Navigating NLSP Stock: NLS Pharmaceutics Ltd Journey - The InvestChronicle
NLS Pharmaceutics Ltd (NASDAQ: NLSP) Defies Bearish Expectations and Displays Strong Future Potential - Marketing Sentinel
NLS and Kadimastem move forward with merger plans - MSN
Israeli startup Kadimastem to merge With NLS Pharmaceutics - MSN
NLS Pharmaceutics to Participate in the 23rd Annual H.C. Wainwright Global Investment Conference - ACCESS Newswire
NLS and Kadimastem move forward with merger plans By Investing.com - Investing.com Canada
NLS Gains on Deal with Kardimastem - Baystreet.ca
Kadimastem Shareholders Greenlight Merger with NLS - Sleep Review
NLS Pharmaceutics Amends Merger Agreement with Kadimastem - TipRanks
0.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):